Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …

BACKGROUND Cyclins and cyclin-dependent kinases (CDKs) drive cell division. Of
particular importance to the cancer field are D-cyclins, which activate CDK4 and CDK6. In …

Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) have recently
entered the therapeutic armamentarium of clinical oncologists, and show promising activity …

Inhibiting the cell-cycle kinases CDK4 and CDK6 results in significant therapeutic effect in
patients with advanced hormone-positive breast cancer. The efficacy of this strategy is …

Genetic alterations affecting RAS proteins are commonly found in human cancers. Roughly
a fourth of melanoma patients carry activating NRAS mutations, rendering this malignancy …

The regulation and function of cyclin‐dependent kinase 6 (CDK6)‐and cyclin‐dependent
kinase 4 (CDK4)‐cyclin complexes are commonly altered with enhanced kinase activity …

Three inhibitors of CDK4/6 kinases were recently FDA approved for use in combination with
endocrine therapy, and they significantly increase the progression-free survival of patients …

Targeting MAPK pathway using a combination of BRAF and MEK inhibitors is an efficient
strategy to treat melanoma harboring BRAF-mutation. The development of acquired …

The uncontrolled proliferation of cancer cells has led to the development of small-molecule
inhibitors to target cell-cycle progression. Palbociclib, ribociclib, and abemaciclib are ATP …